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Remodeling Without Recovery of Cardiac Energetics*J. Eduardo Rame, MD, MPHIL,a Emma J. Birks, MD, PHDbD espite impressive changes at the organ, tis-sue and cellular level in myocardial reverseremodeling with left ventricular assist de-
vice support, reprogramming the presumed “end-
stage” human heart toward the nonfailing phenotype
has not been convincingly demonstrated (1–5). Many
have questioned the possibility of achieving sus-
tained myocardial “recovery” using our current tech-
nology, leading to a call for further investigation by a
recently gathered National Heart, Lung, and Blood
Institute task force (6). Metabolic adaptations have
been reported in the calorie-restricted, exercising,
ischemic, and failing myocardium—and recently, the
lipidomic signature of the end-stage failing, nondia-
betic human heart has revealed rareﬁed lipid stores
and evidence for a newly discovered shift to ketones
as an alternative energy fuel (7–10).SEE PAGE 432Enter the highly anticipated work by Diakos et al.
(11) to ﬁll in the translational knowledge gaps be-
tween myocardial recovery and metabolic adaptation
after left ventricular assist device (LVAD) support.
The authors performed targeted and untargeted
quantitation of metabolites with mass spectroscopy
to characterize the metabolic phenotype of myocar-
dial reverse remodeling with mechanical unloading in
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plantation after LVAD support. Their analyses
revealed the following signatures: 1) increased
glycolytic ﬂux without a commensurate increase in
glucose oxidation resulting in increased myocardial
pyruvate and shuttled lactate levels; 2) a persistent
disruption in the tricarboxylic acid (TCA) cycle char-
acterized by splitting between ﬁrst-span and second-
span levels of intermediates; 3) a deﬁcit in mito-
chondrial oxidative capacity with decreased State III
and State IV respiration in the chronically failing
heart not improved with mechanical unloading; and
4) decreased density and altered structure of mito-
chondria in failing hearts pre- and post-mechanical
unloading. The authors (11) reason that the decou-
pling of the utilization of glucose in the failing
myocardium—glycolysis from oxidation—is linked
with deﬁcits in mitochondrial function, both in the
cycling of intermediary metabolites and oxidative
phosphorylation. In order to interpret the signiﬁcance
of these ﬁndings, we ﬁrst need to step back and un-
derstand the current work in the context of recent
advances in our understanding of the metabolic
adaptation of the failing heart. Second, we need to
ask exactly what are the mechanisms behind this
remodeling in the adaptive metabolism of the failing
heart that fall well short of recovering the cardiac
energetics with mechanical assist device support?
Muscle, both cardiac and skeletal, has a high de-
gree of plasticity to the changing conditions chal-
lenging its environment. In response to a change in
loading conditions and loss of contracting mass and
function, metabolic adaptations have been demon-
strated in the failing mammalian heart including
decreased utilization of fatty acids with a shift to the
more oxygen-sparing energetic substrate of glucose
(12–14). The work by Diakos et al. (11) convincingly
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446demonstrates decreased levels of glucose-1-
phosphate and glucose-6-phosphate in the end-
stage failing myocardium, which is indicative of a
decreased utilization of glucose, and is consistent
with decreased glycolysis in advanced heart failure.
The importance of this ﬁnding, coupled with the
demonstration that with mechanical unloading there
is an increase in the levels of glycolytic metabolites is
extremely important, insofar as it shows that there is
not a uniform shift to increased glucose metabolism
across the broad spectrum of heart failure. Instead,
these data support the dynamic model of metabolic
adaptation across the different stages of heart failure,
with speciﬁc metabolic signatures apparent in re-
sponders versus non-responders. Indeed, although
not large enough for analysis, the subgroup of pa-
tients with signiﬁcant myocardial functional
improvement after mechanical unloading did show
greater mitochondrial functional and structural
improvement than the “nonresponders.” A study
investigating the metabolic phenotype of nonselec-
tive adrenergic receptor blockade in chronic human
heart failure with 18-ﬂuoro-deoxyglucose positron
emission tomography demonstrated an increased
uptake of glucose in the patients with the most sig-
niﬁcant degree of myocardial reverse remodeling and
improved left ventricular ejection fraction (15). Thus,
an improved myocardial phenotype may shift more
towards increased reliance on glucose metabolism.
The work by Diakos et al. (11) extends the observation
of myocardial plasticity in metabolic adaptation to
the end-stage failing heart transitioning to mechani-
cal support and provides evidence of increased
glucose utilization through glycolysis but without the
capacity to couple this with the oxidation of pyruvate
and increased oxidative metabolism.
When considering the impact of these results on
future investigation, an important question concerns
the mechanism of how glycolytic ﬂux becomes
uncoupled from glucose oxidation. This uncoupling
results in a bottleneck increasing the myocardial
levels of pyruvate and lactate above the nonfailing
levels after a period of mechanical unloading. Could
the increase in glycolysis be the result of improving
myocardial insulin resistance that has been reported
after LVAD therapy (16,17), with the bottleneck at
pyruvate representing a failure to release the brake
on pyruvate dehydrogenase (PDH) caused by the
excess circulating fatty acids? In essence, the effects
of the Randle Cycle (18)—inhibition of glucose
oxidation by fatty acid uptake and utilization—may
persist until the complete reversal of the heart failure
syndrome with subsequent normalization of the
peripheral metabolic milieu. Alternatively, is theincreased concentration of glycolytic metabolites the
result of a “shift back to glucose” and away from ke-
tone metabolism (7,8), as peripheral insulin signaling
improves, effectively decreasing or halting hepatic
ketogenesis? If so, there may be a novel link switch-
ing cardiac substrate utilization on/off under failing
conditions which accompanies the metabolic reprog-
ramming to an earlier stage of heart failure marked by
a preferential metabolism of glucose.
Diakos et al. (11) have correctly identiﬁed abnor-
malities in mitochondrial structure and function in
the failing heart that persist after a period of me-
chanical unloading, invoking this broader mechanism
as the reason for the impaired oxidation of glucose
and the decoupling from glycolysis. They present
very convincing data that the TCA cycle, which was
recently demonstrated to be disrupted in advanced
heart failure with a decreased ratio of succinyl-CoA
(an early second-span intermediate) to acetyl-CoA
(the proximal metabolic point of entry), remains
abnormal despite effective mechanical unloading
with LVAD therapy (8). A proposal is made by the
authors that mechanisms involving anaplerosis and
cataplerosis interacting with amino acid metabolism
can explain the changes in the intermediate metabo-
lites of the Krebs cycle. However, what remains un-
explained is the difference in post-LVAD levels
between ﬁrst-span (remain decreased) and second-
span (restored to non-failing levels) intermediates.
Precisely why are the metabolites after succinyl-CoA
restored as the end-stage failing heart remodels
with mechanical unloading? This may again represent
a “switch away from ketones” because succinyl-CoA
is no longer shuttled from the TCA cycle to serve as
the CoA donor in the rate-limiting step of ketone
oxidation through the enzyme SCOT (succinyl-CoA:3-
oxoacid CoA transferase) that was demonstrated to be
signiﬁcantly up-regulated in the end-stage failing
human heart (8) (Figure 1). Thus, the active oxidation
of ketones results in a depletion of succinyl-CoA
while reversing this state through a decrease or
halting of ketogenesis restores the myocardial pool of
succinyl-CoA and second-span TCA cycle in-
termediates. Given the importance of succinylation
and acetylation in the transcriptional and enzymatic
control of important metabolic pathways, the
myocardial concentration of succinyl-CoA may play a
key role in the regulation of metabolic adaptations
across the various stages of heart failure.
What are the therapeutic implications of this work
in the ﬁeld of myocardial recovery with LVAD ther-
apy? It should be noted that the present study by
Diakos et al. (11) focused on the effects of mechani-
cal unloading rather than the metabolic signature of
FIGURE 1 Restoring the Pool of Succinyl-CoA and Second Span TCA Cycle Intermediates With Reversal of Adaptive Ketone Metabolism
The illustration demonstrates the proposed link between the decreased pool of succinyl-CoA that is necessary for Krebs (tricarboxylic acid
[TCA]) cycling and the presence of ketone oxidation because the rate-limiting enzyme OXCT1 (also known as SCOT, succinyl-CoA:3-oxoacid CoA
transferase) requires succinyl-CoA as a CoA donor for acetoacetate to yield acetoacetyl-CoA. Thus, increased myocardial ketone oxidation in the
end-stage failing heart results in a decreased pool of succinyl-CoA and other second-span TCA cycle intermediates (succinate, fumarate). With
the reversal of heart failure achieved with mechanical unloading, hepatic ketogenesis may be decreased resulting in a shift away from
myocardial ketone oxidation, restoring the pool of succinyl-CoA and second-span TCA intermediates and explaining the observations by Diakos
et al. (11). Illustration adapted from Bedi et al. (8). FFA ¼ free fatty acid.
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447recovery because these were paired samples from
patients bridged to transplantation. We are
approaching the ﬁnal follow-up phase of the pro-
spective, multicenter study of myocardial reverse
remodeling with LVAD and standard optimized heart
failure therapies (ReSTAGE HF [Remission from
Stage D Heart Failure]). The ReSTAGE-HF study was
designed to evaluate the rate of recovery when
centers optimize pump speed for unloading and use
optimal heart failure therapy. By including inter-
mittent testing of underlying function at set time
points in a common protocol the rate of recovery
under “best standard” conditions will be deter-
mined. Once this has been established the next
phase will be to consider adjunctive therapies, that
is, drugs and strategies that can be added, to ﬁrstly
further promote reverse remodeling and enhance the
rate and degree of myocardial reverse remodeling,
and secondly and importantly, to enhance its dura-
bility. Previously, the Hareﬁeld, United Kingdom,
group successfully added clenbuterol as an adjunc-
tive second stage of the therapy, which was done to
enhance the durability of recovery (1). Adding a
period of cardiac reloading before explantation isalso likely to be beneﬁcial, and the work by these
authors suggests this might have beneﬁcial effects
on mitochondrial structure and function. Like exer-
cise, which has been shown to improve mitochon-
drial function, cardiac reloading may prove to be an
important addition to recovery protocols. The cur-
rent study also suggests that novel drugs targeting
mitochondrial function and enhancement of meta-
bolic adaptation might serve as important additions
to recovery protocols to improve the myocardial
function and durability of the therapeutic approach.
Starting with this important contribution by Diakos
et al. (11), further understanding of the metabolic
phenotypes resulting from the reversal of heart failure
is likely to enhance, not only our rate of myocardial
recovery, but the durability after explantation that
may be the real target in our efforts to reprogram the
failing human heart.
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